Intravenous iron in inflammatory bowel disease

Table 2 Characteristics of the clinical trials involving IBD patients that compared IV iron administration with oral iron or no intervention included in this review

Study (yr)	n	Study design	Compound	Baseline Hb(g/dL)	Total dose, mg (schedule)	Duration (wk)	Response (%)	DCT (%)
Gasche et al[31] (2001)	103	Multicentre, open-label	Iron sucrose	≤ 10.5	1200 mg (6 × 200 mg)	4	65	0
Bodemar et al[32] (2004)	59	Retrospective	Iron sucrose	< 12	Mean 1400 mg (1-2 × 200 mg/wk)	8	60	0
						12	91
Schröder et al[14] (2005)	46	Multicentre randomized open-label	Iron sucrose (22)	< 10.5 (F)	Mean 1418 mg (7 mg/kg + 5 × 200 mg)	6	55	4.5
			Ferrous sulfate (24)	< 11 (M)	Mean 5600 mg (100-200 mg/d)		53	20.8
García-López et al[35] (2006)	70	Single centre prospective observational	Iron sucrose	< 10.51	Mean 920 mg (200-1800 mg) (200 mg/1-3 times a week)	Mean 5 (1-9 )	67	0
Kulnigg et al[37] (2008)	200	Multicentre randomized open-label	Ferric carboxymaltose (137)	≤ 10	1000-1500 mg (1-2 infusion of 500-1000 mg)	12	77	1.5
			Ferrous sulfate (63)		16 800 mg (200 mg/d)		68	7.9
Lindgren et al[33] (2009)	91	Multicentre randomized investigator-blinded	Iron sucrose (45)	< 11.5	Mean 1700 mg (200 mg/1-2 wk)	20	66	7
			Ferrous sulfate (46)		Mean 38 400 mg (200-400 mg/d)		47	22
Gisbert et al[34] (2009)	100	Multicentre, open-label	Iron sucrose (22)	< 10	Not reported (2 × 200 mg/wk if Hb < 10)	26	77	0
			Ferrous sulfate (78)	> 10	19 000 mg (106 mg/d)		89	5.1

¹Also no response or intolerance to oral iron or clinical need of quick recovery of anemia. ΔHb ≥ 2 g/dL or normal Hb; DCT: Discontinuation due to serious adverse events; F: Female; M: Male.